Fertility Market Poised For Growth Spurt After Fallow Decade
This article was originally published in Pharmaceutical Approvals Monthly
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.
You may also be interested in...
UCB’s Cimzia wins ankylosing spondylitis claim, but axial spondyloarthritis is not looking good; GE’s Vizamyl joins Amyvid on list of underemployed amyloid imagers; Cubist stretches Entereg label a bit; Iroko builds a safer NSAID; and more.
Women trying to get pregnant are seeking personalized, accurate, actionable information about fertility, and health IT and medtech start-ups are answering this need via the power of data. Profiles of Fertility Focus, OvuLine, and Univfy.
Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.